enVVeno Medical (NVNO) Stock Price, News & Analysis

Company Overview

enVVeno Medical Corporation (NASDAQ: NVNO) is a medical device company focused on developing bioprosthetic solutions for vascular and cardiovascular diseases. The company’s technologies are designed to address conditions for which existing medical and surgical treatments may be limited or ineffective.

Its lead product candidate is the VenoValve, an investigational surgically implanted tissue-based valve intended to treat chronic deep venous insufficiency, including symptoms associated with post-thrombotic syndrome. The device is designed to help restore one-way blood flow in the deep veins of the leg and reduce venous hypertension. VenoValve has been evaluated in clinical studies and remains subject to regulatory review.

enVVeno also has pursued transcatheter heart-valve technologies, including the enVVe system, which is intended to treat certain forms of tricuspid regurgitation. The company was formerly known as Hancock Jaffe Laboratories and adopted the enVVeno Medical name in 2021. It is headquartered in Nashville, Tennessee, and its products are in development and regulatory stages rather than broadly marketed commercial products.

Key Stats

• Today's Range: $8.41 to $9.58
• 50-Day Range: $7.80 to $11.80
• 52-Week Range: $7.01 to $30.80
• Volume: 36,538 shs
• Average Volume: 25,688 shs
• Market Capitalization: $6.04 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

enVVeno Medical Stock Analysis - MarketRank™

enVVeno Medical scored higher than 32% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Hold

Consensus Rating

enVVeno Medical has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and 1 sell rating.

Amount of Analyst Coverage

enVVeno Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for enVVeno Medical are expected to grow in the coming year, from ($16.19) to ($6.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of enVVeno Medical is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of enVVeno Medical is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

enVVeno Medical has a P/B Ratio of 0.21. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.29% of the float of enVVeno Medical has been sold short.

Short Interest Ratio / Days to Cover

enVVeno Medical has a short interest ratio ("days to cover") of 0.69, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in enVVeno Medical has recently increased by 44.09%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

enVVeno Medical does not currently pay a dividend.

Dividend Growth

enVVeno Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

enVVeno Medical has a news sentiment score of 1.28. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for enVVeno Medical this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, enVVeno Medical insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $123.00 in company stock.

Percentage Held by Insiders

15.00% of the stock of enVVeno Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

34.71% of the stock of enVVeno Medical is held by institutions.

Company Calendar

• Last Earnings: 7/30/2026
• Today: 10/10/2026
• Next Earnings (Estimated): 10/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Equipment
• Current Symbol: NASDAQ:NVNO
• CIK: 1661053
• Web: www.envveno.com
• Phone: (949) 261-2900
• Fax: 949-261-2992
• Employees: 33
• Year Founded: 1987

Profitability

• EPS (Trailing Twelve Months): ($19.33)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$19.47 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -62.28%
• Return on Assets: -56.83%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 11.70
• Quick Ratio: 11.70

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $41.38 per share
• Price / Book: 0.21

Miscellaneous

• Outstanding Shares: 690,000
• Free Float: 591,000
• Market Cap: $6.04 million
• Optionable: No Data
• Beta: 1.29